AURORA SPINE CORPORATION ANNOUNCES AMENDMENT TO LOAN FROM INSIDER
MWN-AI** Summary
Aurora Spine Corporation, headquartered in Carlsbad, California, announced on March 4, 2026, a significant amendment to an existing loan from an insider totaling US$1,600,000, along with accrued interest of US$1,249,500. The proceeds from this loan have been utilized for general corporate purposes. Following the amendment, the interest rate on the loan was reduced from 9% to 4.5% per annum, effective January 1, 2026. The agreement also extends the maturity date for repayment from June 29, 2027, to July 11, 2029.
In the event of default, the outstanding balance would accrue interest at a rate of 12% or the maximum allowable under law. The agreement specifies that a change of control at the company would trigger an acceleration, requiring the loan to be repaid in full upon the holder's written request. The company retains the flexibility to prepay any outstanding amounts without incurring penalties. Aurora Spine's wholly-owned subsidiary continues to provide a guarantee for the loan's obligations.
As a related party transaction governed by Multilateral Instrument 61-101, this arrangement is exempt from the formal valuation and minority approval processes typically required. The company did not possess the capacity to file a material change report in advance of the loan's amendment completion.
Aurora Spine is known for its innovative spinal implants and pain management technologies aimed at enhancing surgical outcomes through cost-effective solutions. The company emphasizes its commitment to advancing global patient care. As part of standard practice, investors are reminded to consider the inherent risks in forward-looking statements made by the company regarding the loan's repayment and other financial expectations.
MWN-AI** Analysis
Aurora Spine Corporation has recently announced key amendments to its insider loan agreement, which has significant implications for both the company and its investors. The principal amount of the loan stands at $1.6 million, with accrued interest totaling $1.25 million. The most notable change is the reduction in the interest rate from 9% to 4.5%, effective January 1, 2026. This reduction, along with the extended maturity date to July 11, 2029, improves the company's liquidity position and reduces its cost of debt, which is critical for ongoing operations and future growth.
For investors, these amendments could signal a more stable financial outlook for Aurora Spine. By lowering borrowing costs, the company can allocate more resources towards innovation and product development in the competitively evolving market of spinal implants and pain management technologies. The extension of the loan’s maturity offers additional flexibility, allowing the company to navigate potential market headwinds without immediate pressure on its cash flow.
However, investors should be cautious of the embedded risks. The provision that allows for acceleration of the maturity date upon a change of control introduces uncertainty, as this could compel the company to repay the loan swiftly, potentially straining its financial position. Additionally, the high interest rate penalty of 12% following an event of default could pose a risk if cash flow challenges arise.
In conclusion, while the amendment to the loan agreement positions Aurora Spine favorably by reducing financial burdens, prospective and current investors should remain vigilant about the company’s operational performance and market conditions. As always, diversification remains key to managing risks associated with such investments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Carlsbad, California, March 04, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF) announced today this it has amended an existing loan (the "Loan") in the principal amount of US$1,600,000 plus accrued and unpaid interest in the amount of US$1,249,500 from an insider of the Company. The Company has been using the Loan proceeds for general corporate purposes.
The Loan, evidenced by a promissory note (the "Note") bears interest at 9% per annum. The Amendment reduces the interest rate to 4.5% per annum effective January 1, 2026. If an Event of Default occurs and continues, the outstanding balance of the Note, including all accrued and unpaid interest, will bear interest at a rate of Twelve Percent (12%) per annum, or at the maximum rate of interest under applicable law. The Principal Amount together with interest thereon, was due on the Maturity Date of June 29, 2027. The parties have agreed to extend the Maturity Date to July 11, 2029. The parties also agreed that upon a Change of Control of the Company, the Maturity Date will be accelerated, and the Note will be due and payable in full, upon written request from the Holder. The Company may prepay the outstanding principal amount and accrued and unpaid interest thereon, in whole or in part, at any time without penalty. The Company's wholly owned subsidiary, Aurora Spine, Inc., continues its guarantee and security for the obligations of the Company under the Note.
The Loan constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") and the policies of the TSX Venture Exchange but is otherwise exempt from the formal valuation and minority approval requirements of MI 61-101. The Company was not in a position to file a material change report more than twenty-one days in advance of the completion of the Loan.
The Loan is subject to certain conditions including, but not limited to, the receipt of all necessary approvals.
Neither the TSX Venture Exchange, nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), accepts responsibility for the adequacy or accuracy of this release.
About Aurora Spine
Aurora Spine Corporation (TSXV: ASG) (OTCQB: ASAPF) is an innovative designer and manufacturer of minimally invasive spinal implants and interventional pain management technologies. Headquartered in Carlsbad, California, the company’s mission is to improve spinal surgery outcomes through simplified, integrated, and cost-effective solutions that advance patient care worldwide.
Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains statements that constitute “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking statements”). Forward-looking statements include, but are not limited to, statements regarding the manner and timing of repayment of the Loan.
Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on forward-looking statements. Aurora Spine undertakes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws.
Company and Investor Contacts
Aurora Spine Corporation
Trent J. Northcutt
President and Chief Executive Officer
Phone: (760) 424-2004
Chad Clouse
Chief Financial Officer
Phone: (760) 424-2004
Investor Relations
Adam Lowensteiner
Lytham Partners
Phone: (646) 829-9702
Email: asapf@lythampartners.com
FAQ**
How will the amendment to the loan interest rate for Aurora Spine Corp ASAPF impact the company's overall financial health and cash flow moving forward?
What specific corporate purposes has Aurora Spine Corp ASAPF allocated the loan proceeds for, and how does this align with their long-term strategy?
Given the related party transaction nature of the loan, what measures is Aurora Spine Corp ASAPF taking to ensure transparency and protect minority shareholders' interests?
What potential risks could Aurora Spine Corp ASAPF face regarding the accelerated Maturity Date in case of a change of control, and how is the company preparing to mitigate these risks?
**MWN-AI FAQ is based on asking OpenAI questions about Aurora Spine Corp (OTC: ASAPF).
NASDAQ: ASAPF
ASAPF Trading
-3.21% G/L:
$0.1929 Last:
52,623 Volume:
$0.1993 Open:
